Dry powder composition comprising long-chain RNA
The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
1. A method for preparing a dry powder comprising a long-chain RNA molecule, wherein the method comprises the following steps:
a) providing a liquid comprising the long-chain RNA molecule, wherein the long-chain RNA molecule is in a complex with a cationic or polycationic compound, wherein the long-chain RNA molecule comprises more than 200 nucleotides,
b) drying the liquid provided in step a) by spray-freeze drying to produce a dry powder composition, wherein the spray-freeze drying comprises a step of atomization of the liquid at a temperature below −50° C.
2. The method of claim 1 , wherein the dry powder composition comprises a plurality of particles.
3. The method of claim 1 , wherein the dry powder composition has a residual moisture content of 7% (w/w) or less.
4. The method of claim 1 , wherein the dry powder composition has a median particle size in a volume weighted distribution is at least 1 μm.
5. The method of claim 1 , wherein the dry powder composition has an average sphericity of the particles is in a range from 0.7 to 1.0.
6. The method of claim 1 , wherein the long-chain RNA molecule comprises at least one open reading frame (ORF) encoding a protein or a peptide.
7. The method of claim 1 , wherein the long-chain RNA molecule is an mRNA molecule.
8. The method of claim 1 , wherein the long-chain RNA molecule comprises at least one modification.
9. The method of claim 1 , wherein the dry powder composition comprises at least one further excipient.
10. The method according to claim 1 , wherein the liquid comprising the long-chain RNA molecule further comprises at least one excipient selected from a cryoprotectant, a lyoprotectant and a bulking agent.
11. The method according to claim 1 , wherein the liquid comprising the long-chain RNA molecule does not contain a lipid compound.
12. The method according to claim 1 , wherein the drying comprises a step of spray-freezing and a step of lyophilization.
13. The method according to claim 1 , wherein the droplets resulting from the atomization of the liquid are characterized by a mass median aerodynamic diameter of 300 nm to 200 μm.
14. A pharmaceutical composition comprising or consisting of the dry powder composition produced by the method of claim 1 .
15. The method according to claim 1 , wherein the cationic or polycationic compound is a cationic or polycationic polymer, a cationic or polycationic peptide or protein, and/or a cationic or polycationic lipid.